PharmEasy might need to sell Thyrocare

The diagnostics firm was acquired at great cost, but is unable to support PharmEasy’s core online pharmacy business.

1 February, 202310 min
0
PharmEasy might need to sell Thyrocare

Why read this story?

Editor's note: Just a few months ago, it looked like PharmEasy was well on the way to listing on the public markets at a valuation of over $5 billion. But with investors fast losing their appetite for technology stocks in recent months, the online drugs and medical services startup shelved its IPO in November. Now, some of the decisions it took in the run-up to the withdrawn public offer are beginning to bite. In particular, its acquisition of diagnostics chain Thyrocare in June 2021, which has become a millstone around its neck, threatening to thwart PharmEasy’s ambition to build India’s biggest pharmacy.  Nothing could be more ironic. Currently, Thyrocare is the best business in PharmEasy’s portfolio, which includes retail and B2B sales of pharmaceuticals, doctor consultations and diagnostic services. Only Thyrocare makes a profit; in 2020-21, it clocked Rs 152 crore. In the same year, API Holdings, PharmEasy’s parent, recorded operational losses of Rs 3,992 crore and posted a net loss of Rs 2,731 crore. PharmEasy acquired Thyrocare almost a year and a half after the COVID-19 pandemic struck, hoping that the …

You may also like

Internet
Story image

FabHotels pivoted to corporate travel for survival. Can it grow?

The challenges of running a budget hotel chain in India forced the decade-old company to quietly shift its focus to a travel management platform for corporate travellers. Now it must face challenges of another kind.

Business
Story image

Infra.Market is a hamster wheel looking at a make-or-break IPO

The construction material supply firm’s scale and profitability may appear shiny, but hide a stark truth. Its use of equity to fund working capital is playing with fire when bigger fish are eyeing its business.

Internet
Story image

The intercity bus bet by Indian startups is having its moment

Gone are the days of ramshackle buses and spotty schedules. Startups now offer a viable alternative to rail and air travel. But the real test lies ahead as they are only getting started.